RealFeedApp Partners combine platforms to develop next-generation cancer therapies
The partnership covers six biologic preclinical programs, five from LaNova Medicines and one from Beijing Tide Pharmaceutical, aiming to combine SBP Group's platforms with Boehringer Ingelheim's global oncology capabilities.
- Field
- business and funding
- What they did
- Boehringer Ingelheim has signed a collaboration agreement worth up to $7.358 billion with Sino Biopharmaceutical to develop next-generation cancer therapies.
- Why it matters
- The partnership aims to combine the early-development capabilities and platforms of SBP Group with Boehringer Ingelheim's global oncology expertise to broaden their drug development portfolio.
#antibody-drug conjugate#t-cell engager#sino biopharmaceutical#lanova medicines#beijing tide pharmaceutical#oncology
